Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q1 2024 Clinical Research Sites Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q1 2024 Clinical Research Sites Update

The clinical research site sector continues to be one of the most active M&A sectors within pharmaceutical services. Clinical research is highly attractive to private equity firms for its strong industry tailwinds, market fragmentation, and synergistic benefits at scale. Additionally, clinical research provides investors exposure to the tailwinds within pharmaceutical services and drug development without any FDA risk.

This quarter, Assured Healthcare Partners formed a new platform through its investment in Tandem Clinical Research. Despite the wave of consolidation initiated in recent years, private equity firms continue to search for platform caliber assets, proof that there is still plenty of room for additional entrants to the market. Provident expects to see more add-on activity and the continued formation of new platforms by private equity firms with an informed investment thesis in the sector.

To print and download the full Clinical Research Sites Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/04/Q1-2024-Clinical-Research-Sites-Newsletter.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]